Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared a post on X:
“Update form CHECKMATE-9DW trial in HCC – Asian population with Ipilimumab and nivolumab, ESMO.
94% with lenva in control arm.
Similar benefit despite higher VHB (62%) – aetiology of no much relevance (again).
Less use of high dose steroids (vs general population).”
